Skip to main content
Premium Trial:

Request an Annual Quote

Genzyme Joins International Initiative to Help Develop Malaria Drugs

NEW YORK (GenomeWeb News) — Genzyme will join an international public/private initiative to develop malaria drugs, the company said yesterday.
 
The company will work with the Medicines for Malaria Venture, MIT’s Broad Institute, and Harvard University to develop treatments by identifying compounds that the company claims offer a new approach to treating the disease.
 
Genzyme said there are four discovery projects ongoing already, but did not disclose their specifics. The company added that any intellectual property stemming from the research will be made available to the MMV for drug development without royalties.  
 
MMV, a non-profit organization aimed at finding new antimalarial treatments, estimates that there are 300 million to 600 million new clinical cases of malaria each year.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.